RTC 1020
Alternative Names: RTC-1020Latest Information Update: 28 Nov 2024
Price :
$50 *
At a glance
- Originator Ripple Therapeutics
- Class Eye disorder therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Wet age-related macular degeneration
Most Recent Events
- 28 Nov 2024 No recent reports of development identified for research development in Wet age-related macular degeneration in Canada (Intravitreous, Implant)
- 20 Oct 2020 RTC 1020 is available for licensing as of 20 Oct 2020. https://www.rippletherapeutics.com/
- 20 Oct 2020 Early research in Wet age-related macular degeneration in Canada (Intravitreous) (Ripple Therapeutics pipeline, October 2020)